Compare Prospect Capital Corporation (PSEC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Prospect Capital Corporation trades at $2.19 (market cap $1.12B), while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.15B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 74.2× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (19.27%). Which is the better fit depends on your goals.
| PSEC | REGN | |
|---|---|---|
Market Cap | $1.12B | $83.15B |
Sector | Financials | Health |
52-Week High | $3.05 | $852.03 |
52-Week Low | $2.11 | $555.51 |
Dividend Yield | 19.27% | 0.47% |
Enterprise Value | — | $77.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $2.19, down 1.79% on the day, with a bearish technical outlook and mixed analyst sentiment. The stock shows a low P/B of 0.39 and has beaten earnings estimates in recent quarters, but revenue volatility and negative net income in 2025 highlight fundamental challenges. Recent news emphasizes its high dividend yield amid portfolio concerns.
The outlook is cautious due to financial deterioration and NAV erosion risks, though the deep discount to book value and consistent dividend payments may appeal to yield-seeking investors. Key risks include declining investment income and persistent underperformance relative to analyst expectations.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% on the day, with a bullish technical signal from moving averages and a neutral RSI near 54. The stock shows strong profitability with a net income margin of 27.86% and consistent earnings beats in recent quarters. However, multiple class-action lawsuits filed in September 2026 allege securities fraud related to a Phase 3 clinical trial disclosure, creating near-term uncertainty.
The outlook remains cautiously optimistic given robust fundamentals and a 69% analyst buy rating, but legal overhangs and a projected earnings dip in 2026 pose risks. Upside hinges on legal resolution and pipeline execution, while downside is capped by institutional support like CalSTRS' recent $79 billion position increase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
